Trial Profile
Ramelteon (Rozerem) in the treatment of sleep disturbances associated with Parkinson's disease.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2010
Price :
$35
*
At a glance
- Drugs Ramelteon (Primary)
- Indications Sleep disorders
- Focus Therapeutic Use
- 10 Nov 2010 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.